Keyphrases
A(H1N1)pdm09
14%
Adenovirus
13%
BA.1
9%
BA.5
9%
BNT162b2
16%
BNT162b2 Vaccine
24%
Breakthrough Infection
10%
Clinical Samples
11%
COVID-19
89%
COVID-19 Pandemic
21%
COVID-19 Vaccine
9%
European Regions
10%
H3N2
11%
H3N2 Virus
10%
Healthcare Workers
13%
Heart Transplant Recipients
13%
Hemagglutinin
10%
Hospitalized Patients
15%
Human Metapneumovirus (hMPV)
14%
Humoral Response
11%
Immune Response
15%
Immunogenicity
19%
Influenza
40%
Influenza A
11%
Influenza A(H3N2)
10%
Influenza B
14%
Influenza Season
18%
Influenza Vaccination
11%
Influenza Vaccine
12%
Influenza Virus
38%
Influenza-like Illness
31%
Israel
100%
Natural Killer Cells
11%
Neuraminidase
10%
Neutralization Activity
12%
Neutralizing Antibodies
17%
NKp46
17%
Omicron Variant
17%
Quantitative PCR
18%
Respiratory Syncytial Virus
15%
Respiratory Viruses
16%
SARS-CoV-2 Variants
14%
Third Dose
11%
Vaccination
26%
Vaccine Effectiveness
15%
Variants of Concern
11%
Viral
15%
Virus
29%
Winter Season
10%
World Health Organization
12%
Immunology and Microbiology
Adenoviridae
10%
Antibody Response
5%
Antibody Titer
9%
Breakthrough Infection
10%
Cladistics
6%
Coinfection
5%
Coronavirinae
6%
COVID-19
48%
Dynamics
8%
Hemagglutinin
9%
Human Metapneumovirus
9%
Human Respiratory Syncytial Virus
13%
Humoral Immunity
11%
Immune Response
16%
Immunogenicity
13%
Immunoglobulin G Antibody
6%
Infectious Agent
8%
Inflammatory Arthritis
7%
Influenza
87%
Influenza A Virus (H1N1)
32%
Influenza A Virus (H3N2)
17%
Influenza B Virus
5%
Influenza Vaccine
19%
Influenza Virus
27%
Influenzavirus A
9%
interferon
7%
Leadership
6%
Lineages
10%
Monoclonal Antibody
5%
Monospecific Antibody
7%
Mouse
10%
Natural Cytotoxicity Triggering Receptor 1
5%
Natural Killer Cell
17%
Neutralization
30%
Neutralizing Antibody
15%
Omicron Coronavirus Variant
33%
Psoriatic Arthritis
5%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Real-Time Polymerase Chain Reaction
10%
Receptor Binding
5%
Respiratory Syncytial Virus Infection
5%
Respiratory Virus
17%
Severe Acute Respiratory Syndrome Coronavirus 2
72%
Spike
17%
Titer
9%
Transplant Procedure
17%
Vaccination Policy
40%
Vaccine Efficacy
57%
Viral Disease
14%
Wild Type
12%
Medicine and Dentistry
Adenoviridae
9%
Coronavirinae
8%
COVID-19
33%
Disease
11%
Flu Like Syndrome
5%
Health Care
7%
Human Metapneumovirus
5%
Humoral Immunity
6%
Immunoglobulin G Antibody
6%
Infection
31%
Influenza A (H3N2)
9%
Influenza A Virus (H1N1)
14%
Influenza A Virus (H3N2)
13%
Influenza B
7%
Influenza Vaccination
10%
Influenza Vaccine
16%
Influenza Virus
7%
Neutralization
7%
Primary Health Care
6%
Public Health
6%
Real-Time Polymerase Chain Reaction
5%
Rheumatoid Arthritis
6%
Sentinel Surveillance
6%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Surveillance System
5%
Symptom
5%
Virus Infection
6%
